New: NCI-funded clinical trial search
Mednet Logo
CommunityRheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

Where in the sequence of biologics would you consider guselkumab for patients with active psoriatic arthritis despite standard DMARD therapy?

3 Answers

Mednet Member
Rheumatology · Mayo Clinic Jacksonville

This is an extremely important question and one that is likely to change as new data becomes available. It is important to remember that psoriatic arthritis (PsA) is a complex and heterogeneous disease and a single approach does not work for every patient. Based on the ACR/NPF 2019 PsA treatment gui...

How do you select bisphosphonate versus denosumab when initiating treatment prompted by opportunistic CT findings of low L1 attenuation and a prevalent vertebral fracture?

1
1 Answers

Mednet MemberInvited Expert
Rheumatology · University of Kansas

Actually, I prefer calcitonin. It has few side effects and does not have the jaw necrosis risk.

How often do you draw screening ANAs for discoid lupus?

3 Answers

Mednet MemberInvited Expert
Rheumatology · Harvard Medical School

Because a positive ANA is associated with an increased risk of progression to SLE in patients with discoid lupus, I routinely check an ANA at the initial visit in virtually all patients. If negative, I repeat it only if new symptoms concerning systemic involvement arise (e.g., joint pain, cytopenias...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

Do you assess baseline salivary gland function before starting treatment in patients with Sjogren's syndrome?

1
1 Answers

Mednet MemberInvited Expert
Rheumatology · University of California, Berkeley and San Francisco

No. Visual assessment of salivary pool and oral mucosa is routinely done. In the initial consultation and management plan, most always, referral to Sjogren's Oral Medicine Specialist is made where whole salivary flow is measured, usually by Unstimulated Whole Salivary Flow Rate (abnormal, less than/...

How do you assess the risk of developing demyelinating disease when initiating TNF inhibitors?

2 Answers

Mednet MemberInvited Expert
Rheumatology · University of Texas MD Anderson Cancer Center

Demyelinating disease (DD) associated with TNF inhibitors is rare. Risk assessment is mostly clinical. TNF should be avoided if there is a personal history of established DD, especially MS. A strong family history in first-degree relatives or concerning neurological symptoms should warrant caution a...

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answers

Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...

How do you envision incorporating CAR-T therapy into your clinical rheumatology practice?

2
4 Answers

Mednet MemberInvited Expert
Rheumatology · Cleveland Clinic

This is an excellent question—one that, for now, might best be explored over a glass of white wine and some lively hand-waving. It’s a question I often find myself reflecting on every time I hear a presentation or read a new paper on the subject. Here’s a brief editorial response outlining how I env...

Would you expect to see severe arthralgias within the first few days of immune-therapy in a patient without history of autoimmune disease?

1
2 Answers

Mednet MemberInvited Expert
Rheumatology · Ohio State University

The short answer is: Absolutely!The long answer is:From a mechanistic standpoint, it is common to see severe arthralgias within days of initiating immune checkpoint inhibition, even in a patient without a prior autoimmune diagnosis.Checkpoint inhibitors rapidly release inhibitory signals on T-cell a...

How do you approach a patient with Paget’s disease of bone with elevated alkaline phosphatase and history of chronic kidney disease?

1
4 Answers

Mednet MemberInvited Expert
Rheumatology · Icahn School of Medicine at Mount Sinai

You can give Zol IV, which is clearly the optimal treatment for active Paget's. Those in the field that treat many such patients just administer this very slowly over 1-2 hours and assure good hydration concomitantly. I have treated a number of patients like this, with this scenario, without any pro...

Is your approach to managing immune related adverse events altered at all in light of COVID-19?

2 Answers

Mednet MemberInvited Expert
Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center

First of all, I wish to thank @Dr. First Last from Johns Hopkins/Sibley for his advice addressing this critical topic.We are all witnessing a rapidly evolving crisis that none of us have been prepared for and it is the right thing to quickly consider as best as we can how the COVID-19 pandemic shoul...